IP Library Granted Patent US 9,828,622
Granted Patent B2
US 9,828,622 · App. 12/990,997 · Granted Nov 28, 2017

Photoactivatable antimicrobial agents and therapeutic and diagnostic methods of using same

Inventors: Tayyaba Hasan (Arlington, MA); Ulysses W. Sallum (Quincy, MA); Sarika Verma (Waltham, MA); Gerard Nau (Sharon, MA)
Assignee: The General Hospital Corporation
C12Q1/34C07D501/52C12Q1/04G01N33/542G01N33/56911G01N2333/986
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,828,622
App. No.
12/990,997
Granted
Nov 28, 2017
Kind
B2
Abstract

The present invention provides photosensitizer compounds for use in detecting beta-lactamase activity. Methods and kits that utilize the photosensitizer compounds of the invention for the detection of, quantitation of, and classification or typing of microbial beta-lactamases.

Claims (12)

1. A method of measuring susceptibility of beta-lactamase secreting bacteria in a sample to a beta-lactam antibiotic, wherein, the method comprises:

(a) contacting the sample with:

(i) a composition comprising a cephalosporin linker compound linked with two benzophenothiazinium chloride (EtNBS) fluorophores (standard); and

(ii) a composition comprising the beta-lactam antibiotic and the cephalosporin linker compound linked with two EtNBS fluorophores (test sample),

wherein, the EtNBS fluorophores are (Z)-5-((9-(diethylamino)-5H-benzo[a]phenothiazin-5-ylidene)amino)pentanoic acid (EtNBS-COOH) derived fluorophores;

(b) light-activating the standard and the test compositions to produce a fluorescence signal;

(c) quantifying the fluorescence signal with a detector to obtain result;

(d) comparing the test result to the standard result; and

(e) if the amount of the measured fluorescence in the test sample is less than the amount of measured fluorescence in the standard sample, then the β-lactamase secreting bacteria is determined to be susceptible to the β-lactam antibiotic.

2. The method of claim 1 , wherein, the EtNBS fluorophores are conjugated to the cephalosporin linker via amide bond.

3. The method of claim 2 , wherein at least one fluorophore is bound at the 3′ position of the cephalosporin linker.

4. The method of claim 3 , wherein, the cephalosporin linker compound linked with two EtNBS fluorophores is a compound of the structure:

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2017
From: NAU, GERARD
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 043940/0202 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 6, 2010
From: HASAN, TAYYABA; SALLUM, ULYSSES W.; VERMA, SARIKA
To: THE GENERAL HOSPITAL CORPORATION
Reel/Frame 025451/0342 →
Continuity (2)
Provisional Application 61050453 · May 5, 2008
Related Publication 20110112059A1 · May 12, 2011